2,461,596 Shares in Scholar Rock Holding Corporation $SRRK Purchased by Holocene Advisors LP

Holocene Advisors LP bought a new position in shares of Scholar Rock Holding Corporation (NASDAQ:SRRK) during the 3rd quarter, Holdings Channel reports. The firm bought 2,461,596 shares of the company’s stock, valued at approximately $91,670,000.

Other hedge funds also recently added to or reduced their stakes in the company. Moody Aldrich Partners LLC grew its holdings in shares of Scholar Rock by 53.5% in the 3rd quarter. Moody Aldrich Partners LLC now owns 101,742 shares of the company’s stock worth $3,789,000 after acquiring an additional 35,481 shares during the period. Norges Bank acquired a new position in Scholar Rock during the second quarter worth $41,628,000. Voya Investment Management LLC boosted its position in Scholar Rock by 18.1% during the third quarter. Voya Investment Management LLC now owns 443,155 shares of the company’s stock worth $16,503,000 after purchasing an additional 67,839 shares in the last quarter. Nan Fung Trinity HK Ltd. purchased a new stake in Scholar Rock during the third quarter worth $1,402,000. Finally, Ensign Peak Advisors Inc grew its holdings in Scholar Rock by 78.8% in the second quarter. Ensign Peak Advisors Inc now owns 600,639 shares of the company’s stock valued at $21,275,000 after purchasing an additional 264,693 shares during the last quarter. 91.08% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, General Counsel Junlin Ho sold 9,580 shares of the business’s stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $46.53, for a total value of $445,757.40. Following the completion of the transaction, the general counsel owned 241,545 shares of the company’s stock, valued at $11,239,088.85. The trade was a 3.81% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Mo Qatanani sold 8,484 shares of the firm’s stock in a transaction that occurred on Monday, February 23rd. The stock was sold at an average price of $47.07, for a total transaction of $399,341.88. Following the sale, the insider owned 98,445 shares in the company, valued at approximately $4,633,806.15. This trade represents a 7.93% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 207,464 shares of company stock valued at $9,157,423 over the last quarter. 13.30% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of research analysts have recently weighed in on the company. Wolfe Research assumed coverage on Scholar Rock in a research report on Tuesday, November 18th. They issued an “outperform” rating and a $42.00 price target for the company. UBS Group began coverage on shares of Scholar Rock in a research report on Wednesday, January 7th. They issued a “buy” rating and a $60.00 price objective on the stock. BMO Capital Markets raised their target price on shares of Scholar Rock from $50.00 to $70.00 and gave the company an “outperform” rating in a report on Wednesday, March 4th. Weiss Ratings restated a “sell (d-)” rating on shares of Scholar Rock in a research report on Thursday, January 22nd. Finally, Piper Sandler upped their price target on shares of Scholar Rock from $51.00 to $58.00 and gave the company an “overweight” rating in a report on Wednesday, March 4th. Four investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Scholar Rock has a consensus rating of “Buy” and a consensus price target of $54.36.

Scholar Rock Stock Performance

NASDAQ SRRK opened at $40.26 on Tuesday. The company has a quick ratio of 6.95, a current ratio of 6.95 and a debt-to-equity ratio of 0.41. Scholar Rock Holding Corporation has a fifty-two week low of $22.71 and a fifty-two week high of $49.82. The business has a fifty day moving average of $45.16 and a 200-day moving average of $39.73. The stock has a market cap of $4.63 billion, a price-to-earnings ratio of -11.74 and a beta of 0.70.

Scholar Rock (NASDAQ:SRRK) last posted its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.76) EPS for the quarter, beating analysts’ consensus estimates of ($0.86) by $0.10. During the same period last year, the business posted ($0.64) EPS. As a group, analysts predict that Scholar Rock Holding Corporation will post -2.42 earnings per share for the current fiscal year.

Scholar Rock Profile

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).